Fecal Lcn-2 serves as a sensitive, non-invasive biomarker for detecting gut dysbiosis and intestinal inflammation in MS. This highlights the role of gut health in MS pathogenesis and suggests potential for monitoring disease progression or response to therapies targeting the gut microbiome. This evidence concerns the gene LCN2 and myeloid sarcoma.